Cannabinoid-based pharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is teaming up with the Canadian Consortium for the Investigation of Cannabinoids to make a continuing education course available to the medical community in Canada.
The course, known as the Canadian Cannabis Syllabus, is accredited by the University of Calgary’s Office of Continuing Medical Education and Professional Development. It was designed to provide healthcare professionals with fundamental knowledge about cannabis and cannabinoid products for clinical practice.
The course is structured into nine modules, covering a range of topics from an introduction to the endocannabinoid system, the basics of cannabis and long-term health issues associated with cannabis, to the clinical use of cannabis and cannabinoids in pain and non-pain conditions.
It also includes modules on considerations when authorizing cannabis, acute adverse effects, drug interactions, contraindications of cannabis, cannabis use disorder, and cannabis policy in Canada.
Read more: Avicanna teams up with Langara College to research cannabinoid formulations
Read more: Shoppers Drug Mart hands its medical cannabis business over to Avicanna
The CCIC is a not-for-profit organization composed of researchers, healthcare professionals and educators. It is dedicated to promoting research and education about the endocannabinoid system, the therapeutic applications of cannabinoids, and the potential risks associated with cannabis use.
Avicanna has a broad portfolio of over thirty products, including the RHO Phyto range of medical cannabis and wellness products, and a pipeline of patent-pending drug candidates for various medical conditions. Avicanna’s first pharmaceutical preparation, Trunerox, is currently in the drug registration stage in South America.
The company is also set to launch MyMedi.ca, a medical cannabis care platform, in August in order to provide comprehensive patient support and educational resources.
Avicanna stock went up by 3.45 per cent on Friday to $0.30 on the Toronto Stock Exchange.
